Quick View
| Metric | Current | Prior | YoY |
|---|---|---|---|
| Revenue | ¥6.6B | ¥6.8B | −3.7% |
| Operating Income | ¥0.5B | ¥1.0B | −55.2% |
| Ordinary Income | ¥0.5B | ¥0.9B | −50.3% |
| Net Income | ¥0.4B | ¥0.9B | −52.9% |
| ROE | 2.4% | 4.9% | - |
Executive Summary
FY2025 Q2 results show revenue of 6.6B yen (YoY -3.7%), operating income of 0.5B yen (YoY -55.2%), ordinary income of 0.5B yen (YoY -50.3%), and net income of 0.4B yen (YoY -52.9%). The company experienced a modest revenue decline coupled with significant profit deterioration. Operating margin compressed to 7.0% from approximately 15.2% in the prior year period, primarily driven by elevated SG&A expenses relative to revenue. While gross profit margin remained solid at 57.9%, the sharp contraction in operating profitability reflects operational efficiency challenges. Operating cash flow turned negative at -2.0B yen, indicating substantial concerns about earnings quality and working capital management.
Performance Drivers
Revenue declined 3.7% YoY to 6.6B yen, reflecting a modest top-line contraction. Despite the relatively small revenue decrease, operating income fell sharply by 55.2% to 0.5B yen, representing a severe profit decline disproportionate to the sales movement. The primary driver of this profit deterioration was the increase in SG&A expenses to 3.3B yen, representing 50.8% of revenue, which rose relative to the prior period when operating margin was approximately 15.2%. Cost of sales at 2.8B yen maintained a gross profit margin of 57.9%, indicating the core business model's pricing power and cost structure remain intact. However, the combination of elevated fixed costs and modest revenue pressure compressed profitability substantially. Operating income to ordinary income showed minimal variance at 0.5B yen each, suggesting negligible non-operating impacts. The gap between ordinary income of 0.5B yen and net income of 0.4B yen reflects normal tax effects with profit before tax at 0.7B yen. No extraordinary items such as impairments or asset sales were disclosed as material factors. The performance pattern is revenue down, profit down significantly, with the profit decline magnitude far exceeding the revenue contraction, highlighting operational leverage and cost structure challenges.
Key Metrics
[Profitability] ROE of 2.4% represents substantial deterioration from historical levels, with operating margin at 7.0% declining from approximately 15.2% in the prior year period. Net profit margin stands at 6.5%, reflecting compressed profitability across the income statement. Gross profit margin of 57.9% remains robust, but SG&A ratio of 50.8% indicates operational efficiency challenges. [Cash Quality] Cash and deposits of 12.1B yen provide substantial liquidity coverage at 12.09 times short-term debt, though operating cash flow turned negative at -2.0B yen, representing -4.74 times net income and signaling significant earnings quality concerns. [Investment Efficiency] Asset turnover of 0.31 reflects moderate asset utilization, with capital expenditure of 0.4B yen at 0.76 times depreciation and amortization of 0.6B yen, suggesting relatively conservative investment levels. [Financial Health] Equity ratio of 84.6% indicates a highly capitalized balance sheet with total equity of 18.1B yen against total assets of 21.4B yen. Current ratio stands at 526.3% with current assets of 16.5B yen covering current liabilities of 3.1B yen by a wide margin. Debt-to-equity ratio of 0.06 reflects minimal leverage with interest-bearing debt of 1.0B yen consisting entirely of short-term borrowings.
Cash Flow Analysis
Operating cash flow of -2.0B yen represents -4.74 times net income of 0.4B yen, indicating substantial disconnect between reported earnings and cash generation. This negative operating cash flow primarily stems from a significant increase in trade receivables of 1.9B yen or 108.1% YoY, extending days sales outstanding to 202 days and suggesting severe working capital deterioration. Investing cash flow of -0.5B yen was driven by capital expenditures of 0.4B yen, representing 0.76 times depreciation and amortization, indicating maintenance-level investment. Financing cash flow of -1.3B yen reflected share repurchases of 0.4B yen alongside dividend payments, demonstrating continued commitment to shareholder returns despite negative free cash flow. Free cash flow of -2.5B yen indicates the company consumed cash during the period, with shareholder distributions exceeding cash generation capacity. The combination of negative operating cash flow and ongoing capital returns is supported by the company's substantial cash reserves of 12.1B yen, though this trajectory is clearly unsustainable without working capital improvements.
Earnings Quality
Ordinary income of 0.5B yen versus operating income of 0.5B yen shows minimal non-operating contribution, with the difference primarily attributable to normal financial income and expenses. Non-operating items represent less than 1% of revenue, consisting mainly of interest and financial effects without material equity method gains or extraordinary items. The operating cash flow of -2.0B yen compared to net income of 0.4B yen reveals significant quality concerns, with the -4.74 ratio indicating substantial accruals. This accrual buildup stems primarily from the 1.9B yen increase in trade receivables, extending collection cycles to 202 days and suggesting revenue recognition preceding cash realization. The cash conversion ratio below zero and the substantial working capital consumption highlight that reported profits are not backed by corresponding cash flows. While the company maintains high gross margins and lacks apparent non-recurring adjustments, the fundamental disconnect between earnings and cash generation materially diminishes earnings quality until receivables management improves.
Guidance Update
Full-year guidance projects revenue of 16.0B yen (YoY +10.0%), operating income of 3.0B yen (YoY +20.2%), and ordinary income of 3.0B yen (YoY +24.5%). Through Q2, revenue progress stands at approximately 41% of the full-year target, while operating income progress is approximately 15%, both tracking below the standard 50% midpoint expectation. This suggests the company anticipates significantly stronger second-half performance to achieve guidance, requiring substantial acceleration in both top-line growth and profitability improvement. The implied second-half operating margin would need to expand materially beyond Q2 levels of 7.0% to reach the full-year operating income target. Given Q2's negative operating cash flow and extended receivables cycle, achieving guidance depends critically on working capital normalization and SG&A cost control. The forecasted EPS of 45.68 yen supports an annual dividend of 18.00 yen, implying a payout ratio of approximately 39% at the full-year guidance level, substantially lower than Q2's unsustainable 206.5% payout ratio based on actual earnings.
Shareholder Returns
Annual dividend forecast is 18.00 yen per share, with no interim dividend paid in Q2. Based on Q2 basic EPS of 7.74 yen, the full-year dividend implies a payout ratio of 206.5% relative to current run-rate earnings, representing an unsustainable distribution level that exceeds net income. The company executed share repurchases of 0.4B yen during the period, increasing treasury stock and demonstrating active capital allocation toward shareholder returns. Total shareholder returns combining dividends and buybacks amount to approximately 1.7B yen annualized, which substantially exceeds free cash flow of -2.5B yen in Q2. While the company maintains substantial cash reserves of 12.1B yen to support distributions, the current trajectory with negative free cash flow and payout ratios exceeding 200% is clearly non-sustainable. If full-year guidance is achieved with net income improving to levels supporting the forecasted EPS of 45.68 yen, the payout ratio would normalize to approximately 39%, representing a more sustainable level. The total return ratio combining dividends and buybacks relative to earnings remains elevated and requires monitoring alongside cash flow improvement.
Risk Factors
Working capital deterioration represents the most critical risk, with trade receivables increasing 108.1% YoY to extend days sales outstanding to 202 days. This receivables cycle expansion consumes substantial cash and creates collection risk, with operating cash flow turning negative at -2.0B yen despite positive net income. Second, the company faces profitability pressure from elevated SG&A expenses reaching 50.8% of revenue, compressing operating margin to 7.0% from approximately 15.2% in the prior year. Without cost structure realignment, achieving full-year guidance requiring stronger second-half margins becomes increasingly challenging. Third, the company maintains 100% short-term debt composition with all 1.0B yen of borrowings classified as current, creating refinancing risk despite strong liquidity. The combination of negative free cash flow and elevated shareholder distributions of 1.7B yen annualized depletes cash reserves at an unsustainable pace, requiring either operational improvement or capital allocation adjustments.
Industry Benchmark (Reference - Proprietary Data)
[Industry Position] (Reference - Proprietary Analysis) The company's ROE of 2.4% significantly underperforms the IT and Telecom industry median of 5.6%, ranking below the 25th percentile and indicating substantial profitability challenges relative to peers. Operating margin of 7.0% falls well below the industry median of 14.0%, positioning at the lower quartile with margins closer to the 3.8% first quartile threshold. Net profit margin of 6.5% similarly trails the industry median of 9.2%. The company's equity ratio of 84.6% substantially exceeds the industry median of 60.2%, placing in the upper quartile above 88.4% and reflecting conservative capitalization. However, this financial strength is offset by operational underperformance, with revenue declining 3.7% YoY versus industry median growth of 21.0%, representing bottom-quartile performance. Asset turnover of 0.31 aligns closely with the industry median of 0.35, suggesting comparable efficiency in asset utilization. Days receivables outstanding of 202 days far exceeds the industry median of 117 days, highlighting material working capital management challenges. The company's cash conversion ratio turns negative while the industry median stands at 1.22, indicating severe underperformance in converting earnings to cash. Current ratio of 526.3% substantially exceeds the industry median of 7.74 times, though this primarily reflects high cash balances rather than operational strength. (Industry: IT and Telecom, N=7 companies, Period: FY2025 Q2, Source: Proprietary analysis)
Key Takeaways from Earnings
The company exhibits a fundamental disconnect between reported profitability and cash generation, with negative operating cash flow of -2.0B yen despite positive net income reflecting severe working capital deterioration. Days sales outstanding extending to 202 days versus an industry median of 117 days identifies receivables management as the critical improvement area requiring immediate attention. Operating margin compression to 7.0% from 15.2% prior year and significantly below the industry median of 14.0% indicates the company has lost operational efficiency, with SG&A expenses at 50.8% of revenue requiring structural realignment. The combination of negative free cash flow and shareholder distributions totaling 1.7B yen annualized through dividends and buybacks creates an unsustainable capital allocation trajectory, though substantial cash reserves of 12.1B yen provide near-term cushion. Achievement of full-year guidance requiring 10% revenue growth and 20% operating income growth depends critically on second-half execution, working capital normalization, and cost control, representing significant delivery risk given Q2 performance tracking well below midpoint expectations at 41% revenue and 15% operating income progress.
This report was automatically generated by AI analyzing XBRL earnings data as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.
AI Financial Analysis
Executive Summary
FY2026 Q2 performance was weak, with modest revenue contraction translating into a disproportionate decline in operating profit and a material deterioration in cash conversion. Revenue fell 3.7% year on year to ¥659m. Operating income declined 55.2% to ¥46m, while ordinary income declined 50.3% to ¥47m. Net income attributable to owners fell 52.9% to ¥43m, equivalent to EPS of ¥7.74. Gross profit decreased to ¥382m from ¥439m in the prior-year period. The gross margin contracted to 57.9% from 64.1%, a 620bp decline, indicating higher cost intensity despite only a 3.7% revenue decline. SG&A expense was essentially flat year on year at ¥335m, increasing approximately 0.2%, so the lower gross profit flowed directly into operating-margin pressure. The operating margin fell to 7.0% from 15.2%, an 820bp compression. EBITDA was ¥102m and the EBITDA margin was 15.5%, demonstrating that depreciation and amortization of ¥56m remains meaningful relative to EBIT for this laboratory and analytical-services business. Profit before tax of ¥65m exceeded ordinary income because of ¥18m of extraordinary income from reversal of subscription rights to shares; accordingly, reported net income contains a non-recurring uplift. Cash flow quality was the principal negative: operating cash flow was negative ¥204m despite ¥43m of net income, producing an OCF/net-income ratio of negative 4.74x. The cash outflow was primarily associated with a ¥187m increase in trade receivables, consistent with elevated DSO of 101 days. Free cash flow was negative ¥254m after capital expenditures of ¥43m. Nevertheless, liquidity remains exceptionally strong, with ¥1,209m of cash, a 526.3% current ratio, and only ¥100m of interest-bearing debt. The FY2026 forecast requires a pronounced second-half recovery, as Q2 cumulative revenue, operating income and net income represent only 41.2%, 15.3% and 16.5%, respectively, of full-year guidance. The investment focus is therefore on conversion of receivables into cash, restoration of gross margin, and evidence that the second-half revenue ramp can support the company’s ¥300m operating-income target.
Profitability Analysis
The reported annualized DuPont ROE is 4.8%, below the 8% level generally viewed as a minimum healthy return threshold. Its components are a 6.5% net profit margin, annualized asset turnover of 0.617x, and financial leverage of 1.18x. The low leverage is a balance-sheet strength rather than a return concern, as the business is funded predominantly by equity and cash rather than debt. The largest adverse operating change was margin compression: gross margin fell 620bp year on year to 57.9%, and operating margin declined 820bp to 7.0%. Revenue fell ¥25m, whereas gross profit fell ¥57m, showing that the deterioration was driven predominantly by cost of sales rather than volume alone. SG&A rose modestly to ¥335m while revenue contracted, demonstrating negative operating leverage and limited near-term flexibility in the cost base. EBITDA of ¥102m, representing a 15.5% margin, was materially above operating income because depreciation and amortization totaled ¥56m. The JGAAP profit presentation is not affected by reported goodwill amortization; EBITDA pre-goodwill amortization is likewise ¥102m. Interest expense was only ¥1m, and EBIT interest coverage was 44.44x, so financing cost is not a material drag on profitability. The five-factor analysis shows an interest burden above 1.0x because profit before tax benefited from extraordinary income, rather than reflecting a recurring interest advantage. The tax burden was 0.661, corresponding to a 32.6% effective tax rate. Net income quality is weaker than the headline 6.5% net margin suggests because ¥18m of extraordinary income represented approximately 2.7% of revenue and lifted profit before tax. Sustainable profitability therefore depends on recovering the gross margin and scaling revenue against a largely fixed SG&A base, rather than on non-recurring gains.
Growth Assessment
Top-line momentum was negative in Q2, with revenue down 3.7% year on year to ¥659m. The revenue decline was modest in absolute terms, but the associated profit decline was severe because of higher cost intensity and a fixed SG&A base. The full-year plan calls for revenue of ¥1,600m, up 10.0% year on year, and operating income of ¥300m, up 20.2%. Q2 cumulative revenue progress is 41.2% versus a standard first-half progress benchmark of 50%, an 8.8 percentage-point shortfall. Operating-income progress is only 15.3% versus 50%, a 34.7 percentage-point shortfall. Ordinary-income progress is 15.7% versus 50%, and net-income progress is 16.5% versus 50%, both implying substantial back-end loading. To meet guidance, the second half would need to generate approximately ¥941m of revenue, ¥254m of operating income and ¥217m of net income. This implies a required second-half operating margin of roughly 27.0%, versus 7.0% in Q2 cumulative results, making execution on sales mix, project timing and gross-margin recovery especially important. Accounts receivable increased ¥190m year on year to ¥365m, which may reflect revenue recognition timing or longer collection cycles but also increases the importance of conversion to cash. Inventory was limited at ¥20m, but work in process accounted for 51.9% of inventory, indicating that project execution and completion timing can influence period-end revenue and working-capital movements. Capital expenditures of ¥43m were below depreciation and amortization of ¥56m, a 0.76x capex/depreciation ratio; this is not currently a major liquidity burden, though sustained sub-depreciation investment would warrant monitoring for capacity and technology renewal. The business has sufficient cash resources to absorb temporary volatility, but the forecast profile requires clear evidence of a second-half acceleration.
Financial Health
Financial health is strong from a liquidity and leverage perspective. Cash and deposits totaled ¥1,209m, equal to 56.6% of total assets and more than twelve times the ¥100m short-term loan balance. The current ratio was 526.3% and the quick ratio was 520.0%, supported by working capital of ¥1,334m. Total liabilities were only ¥329m, or 15.4% of total assets, while total equity was ¥1,807m. Debt-to-equity was a conservative 0.18x, debt-to-capital was 5.2%, and debt/EBITDA was 0.98x. EBITDA interest coverage of 98.46x confirms that debt service capacity is ample. The maturity profile nevertheless requires attention because 100% of interest-bearing debt is short term, triggering a refinancing-risk alert under the stated benchmark. In context, the refinancing risk is mitigated substantially by cash/short-term debt of 12.09x and very high liquid-asset coverage; it is a maturity-concentration issue rather than a solvency concern. Trade receivables more than doubled year on year to ¥365m and now represent 17.1% of total assets. The associated 101-day DSO is elevated for the stated 60-day alert threshold and creates collection and cash-timing risk. Trade payables rose from ¥4m to ¥17m, partly offsetting the working-capital drain, but the scale of that increase is much smaller than the receivables build. Deferred tax assets were ¥142m, or 6.6% of total assets, and remain a balance-sheet item whose realizability is linked to future taxable profitability. Treasury stock increased to negative ¥211m from negative ¥167m, reflecting the ¥45m share repurchase and reducing reported equity. Lease obligations and asset-retirement obligations are present but are small relative to cash and equity.
Notable B/S Changes
Accounts receivable: +¥190m (+108.1%) to ¥365m - the largest balance-sheet movement and the principal driver of negative operating cash flow; DSO reached 101 days, making collections a key earnings-quality risk. Accounts payable: +¥13m (+337.0%) to ¥17m - percentage growth is high from a low base and provides only limited offset to the much larger receivables increase. Intangible assets: +¥5m (+42.5%) to ¥18m - small in scale at 0.9% of total assets; consistent with modest intangible investment rather than material acquisition-related balance-sheet risk. Treasury stock: -¥45m (-26.9%) to -¥211m - reflects share repurchases of ¥45m, reducing equity modestly while capital return exceeded current-period free cash flow.
Cash Flow Quality
Cash-flow quality was weak in Q2. Operating cash flow was negative ¥204m despite net income of ¥43m, resulting in an OCF/net-income ratio of negative 4.74x versus the 0.8x warning threshold. EBITDA was positive at ¥102m, but OCF/EBITDA was negative 2.00x, confirming that earnings did not convert into operating cash. The principal source of the divergence was a ¥187m increase in trade receivables. Other working-capital outflows included a ¥65m decrease in other payables, a ¥41m reduction in the bonus provision, a ¥31m consumption-tax-related movement and a ¥27m decrease in advances received. A ¥13m increase in trade payables was insufficient to offset these outflows. The 11.5% accruals ratio exceeds the 10% quality-alert threshold, reinforcing that a substantial portion of reported profit has not yet been realized in cash. DSO of 101 days is the most important collection metric to monitor, as a sustained extension could indicate slower customer payment, billing timing effects, or greater reliance on quarter-end revenue recognition. The 51.9% work-in-process share of inventory also merits attention because completion timing can affect both cash conversion and revenue recognition in analytical and contract-service operations. Investing cash flow was negative ¥50m, largely comprising ¥43m of capital expenditure and ¥8m of intangible-asset purchases. Free cash flow was therefore negative ¥254m. Capex/depreciation of 0.76x indicates capital spending was below the depreciation charge during the period, which contained cash outflow but does not offset the working-capital pressure. The company’s ¥1,209m cash reserve provides substantial near-term coverage for the negative free cash flow, but normalization of receivables is necessary for earnings quality to improve.
Dividend Sustainability
No Q2 dividend was declared. The full-year forecast specifies DPS of ¥18.00 and forecast EPS of ¥45.68, implying a forecast dividend payout ratio of approximately 39.4%, which is within a conventionally sustainable range on an earnings basis. Using approximately 5.63 million shares outstanding excluding treasury stock, the indicated full-year cash dividend would be roughly ¥101m. That prospective dividend is manageable against the ¥1,209m cash balance and low debt burden. However, current-period free cash flow was negative ¥254m, so near-term cash coverage depends on the cash reserve and improvement in working-capital conversion rather than internally generated free cash flow. Cash dividends paid were ¥85m during Q2 cumulative cash flow, and share repurchases were ¥45m. Combined dividends paid and buybacks of approximately ¥130m exceeded Q2 cumulative net income of ¥43m, implying a total return ratio of roughly 302% on this period’s earnings; this measure is affected by the timing of dividend payments relative to earnings recognition. The buyback also increased treasury stock by approximately ¥45m year on year, modestly reducing equity but not compromising balance-sheet resilience. Dividend sustainability is therefore strong from a balance-sheet perspective and conditionally sustainable on the full-year earnings forecast, while cash-flow sustainability depends on receivables collection and delivery of the planned second-half profit recovery.
Risk Assessment
Business risks include Revenue and margin execution risk: revenue fell 3.7% year on year, while gross margin contracted 620bp and operating margin contracted 820bp, indicating sensitivity to sales mix, project utilization and cost absorption., Second-half plan risk: achieving FY guidance requires approximately ¥941m of second-half revenue and ¥254m of operating income, equivalent to an implied 27.0% second-half operating margin., Industry-specific project-completion risk: analytical and metabolomics service activity can involve project-based timing, and work in process represented 51.9% of inventory, making delivery timing important for revenue and margin recognition., Collection-cycle risk: DSO of 101 days and a ¥187m increase in trade receivables increase exposure to delayed customer payment and potential revenue-to-cash timing mismatches., Technology and competitive risk: the company’s specialist analytical-services model requires continued relevance of platforms, data capabilities and scientific differentiation, while subdued capex relative to depreciation should be monitored over time..
Financial risks include Earnings-quality risk is high: OCF/net income was negative 4.74x, cash conversion was negative 2.00x, and the accruals ratio was 11.5%., Short-term debt concentration is 100%, above the stated 40% alert threshold. Cash coverage of 12.09x substantially mitigates immediate refinancing exposure, but the maturity concentration remains a financing-structure weakness., Profit before tax included ¥18m of extraordinary income from reversal of subscription rights to shares, reducing comparability of net income with recurring operating performance., Deferred tax assets of ¥142m depend on future taxable-profit generation for full realization..
Key concerns include Highest priority: conversion of the ¥365m receivables balance into cash and reduction of DSO from 101 days., Highest priority: evidence of gross-margin recovery after the Q2 620bp decline., High priority: validation of the sharply back-end-loaded full-year guidance, particularly the implied 27.0% second-half operating margin., Moderate priority: capital-return pacing while free cash flow remains negative, notwithstanding the substantial cash balance., Moderate priority: short-term loan renewal terms and the rationale for maintaining all debt in short-term maturities..
Investment Implications
Key takeaways include Q2 profitability weakened materially: operating income fell 55.2% to ¥46m on a 3.7% revenue decline., The principal operational issue is gross-margin compression, with gross margin down 620bp to 57.9% and SG&A remaining broadly flat., Reported earnings are supported by ¥18m of extraordinary income, while cash earnings were substantially weaker because operating cash flow was negative ¥204m., The balance sheet is a major stabilizer, with ¥1,209m cash, 526.3% current ratio, 0.18x D/E and 0.98x debt/EBITDA., Full-year guidance embeds a demanding second-half recovery and should be assessed against order conversion, project completion and collections..
Metrics to watch include Revenue progress toward the ¥1,600m FY forecast and evidence of acceleration above the Q2 cumulative 41.2% progress rate., Operating-margin recovery toward the full-year target, versus the Q2 cumulative 7.0% margin., Gross margin, cost of sales intensity and SG&A discipline., Trade receivables, DSO and operating cash flow conversion., Work-in-process mix and project completion timing., Cash balance, short-term debt renewal, free cash flow, dividends and additional share repurchases..
Regarding relative positioning, The company is financially conservative relative to typical leveraged growth or laboratory-services businesses, with net cash, very strong liquidity and negligible interest burden. Conversely, its 4.8% annualized ROE and 7.0% operating margin are below the supplied profitability benchmarks, while cash-conversion metrics are materially weak. Relative positioning is therefore defined by balance-sheet resilience rather than current earnings momentum or cash-flow quality.